Azacitidine and venetoclax with or without quizartinib for older or unfit AML patients
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if adding quizartinib to the standard combination of azacitidine and venetoclax improves outcomes for older adults or those with health conditions who cannot have intensive chemotherapy for acute myeloid leukemia (AML). It may help patients with certain genetic changes in the FLT3 or NPM1 genes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed AML that hasn't been treated yet.
- You cannot get standard intensive chemotherapy because of your age (75 or older) or because of other health problems (like heart, lung, or kidney issues).
- You haven't had prior treatment with azacitidine, venetoclax, or quizartinib.
- Your white blood cell count is no higher than 25,000 before starting.
- You don't have active leukemia in your brain or spinal fluid.
- You agree to follow study rules about pregnancy prevention.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a 3-drug combination to treat certain types of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) in adults. It may help by targeting cancer cells using different medicines, especially for people who may not be able to get intensive chemotherapy.
This trial tests if a shorter course of venetoclax, based on early bone marrow results, works as well as the standard longer course. It is for older adults or younger patients with health issues that make standard intensive chemo too risky.
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
This trial tests a combination of two drugs (venetoclax and a hypomethylating agent) plus a targeted FLT3 inhibitor for older or frail patients with a specific genetic change in their acute myeloid leukemia. The goal is to see if this treatment is safe and effective without using the strongest chemotherapy.
This trial tests a combination of three drugs (aclarubicin, azacitidine, and venetoclax) for adults with acute myeloid leukemia (AML) who either cannot have intensive chemotherapy or whose AML has come back after treatment. The goal is to see if this combination is safe and works better.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
Hear when a new Acute Myeloid Leukemia, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.